{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:22:41Z","timestamp":1792041761150,"version":"4.4.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["HL155078"],"award-info":[{"award-number":["HL155078"]}]},{"name":"NIH","award":["HL155078"],"award-info":[{"award-number":["HL155078"]}]},{"name":"NIH","award":["F32HL165838-01"],"award-info":[{"award-number":["F32HL165838-01"]}]},{"name":"NIH","award":["T32EB006359"],"award-info":[{"award-number":["T32EB006359"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>BCR-ABL tyrosine kinase inhibitors (TKIs) have dramatically improved survival in Philadelphia chromosome-positive leukemias. Newer BCR-ABL TKIs provide superior cancer outcomes but with increased risk of acute arterial thrombosis, which further increases in patients with cardiovascular comorbidities and mitigates survival benefits compared to imatinib. Recent studies implicate endothelial cell (EC) damage in this toxicity by unknown mechanisms with few side-by-side comparisons of multiple TKIs and with no available data on endothelial impact of recently approved TKIs or novels TKIs being tested in clinical trials. To characterize BCR-ABL TKI induced EC dysfunction we exposed primary human umbilical vein ECs in 2D and 3D culture to clinically relevant concentrations of seven BCR-ABL TKIs and quantified their impact on EC scratch-wound healing, viability, inflammation, and permeability mechanisms. Dasatinib, ponatinib, and nilotinib, the TKIs associated with thrombosis in patients, all significantly impaired EC wound healing, survival, and proliferation compared to imatinib, but only dasatinib and ponatinib impaired cell migration and only nilotinib enhanced EC necrosis. Dasatinib and ponatinib increased leukocyte adhesion to ECs with upregulation of adhesion molecule expression in ECs (ICAM1, VCAM1, and P-selectin) and leukocytes (PSGL1). Dasatinib increased permeability and impaired cell junctional integrity in human engineered microvessels, consistent with its unique association with pleural effusions. Of the new agents, bafetinib decreased EC viability and increased microvessel permeability while asciminib and radotinib did not impact any EC function tested. In summary, the vasculotoxic TKIs (dasatinib, ponatinib, nilotinib) cause EC toxicity but with mechanistic differences, supporting the potential need for drug-specific vasculoprotective strategies. Asciminib and radotinib do not induce EC toxicity at clinically relevant concentrations suggesting a better safety profile.<\/jats:p>","DOI":"10.1371\/journal.pone.0294438","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:25:59Z","timestamp":1700504759000},"page":"e0294438","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors"],"prefix":"10.1371","volume":"18","author":[{"given":"Yihua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-4996","authenticated-orcid":true,"given":"Richard J.","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-2680","authenticated-orcid":true,"given":"Jennifer L.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-5792","authenticated-orcid":true,"given":"Alec","family":"Stepanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Z.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"15","key":"pone.0294438.ref001","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"R Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"pone.0294438.ref002","unstructured":"SEER CML Facts [Internet]."},{"issue":"24","key":"pone.0294438.ref003","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.","volume":"34","author":"H Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0294438.ref004","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"X Huang","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"pone.0294438.ref005","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies.","volume":"37","author":"TP Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"pone.0294438.ref006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.","volume":"2","author":"J Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"pone.0294438.ref007","author":"NCC Network","year":"2022","journal-title":"Chronic Myleoid Leukemia (Version 3.2022)"},{"issue":"22","key":"pone.0294438.ref008","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"JE Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0294438.ref009","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"TP Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0294438.ref010","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.31557\/APJCP.2018.19.12.3317","article-title":"Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.","volume":"19","author":"Y Mat Yusoff","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"pone.0294438.ref011","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ejca.2013.01.001","article-title":"A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl\/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas","volume":"49","author":"J Portnow","year":"2013","journal-title":"Eur J Cancer"},{"issue":"11","key":"pone.0294438.ref012","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"H Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"23","key":"pone.0294438.ref013","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.","volume":"23","author":"JY Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"pone.0294438.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).","volume":"12","author":"S Cirmi","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"4","key":"pone.0294438.ref015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.","volume":"132","author":"JE Cortes","year":"2018","journal-title":"Blood."},{"issue":"Supplement 1","key":"pone.0294438.ref016","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood-2018-99-113568","article-title":"Prevalence of Comorbidities Relevant to the Choice of Second-Generation (2-G) Tyrosine Kinase Inhibitor (TKI) for the Treatment of Chronic Myeloid Leukemia (CML) in the United States Using Real-World Claims Databases.","volume":"132","author":"EJ Jabbour","year":"2018","journal-title":"Blood"},{"issue":"15","key":"pone.0294438.ref017","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/bloodadvances.2019000034","article-title":"Ponatinib treatment promotes arterial thrombosis and hyperactive platelets","volume":"3","author":"A Merkulova","year":"2019","journal-title":"Blood Adv"},{"key":"pone.0294438.ref018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","article-title":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","volume":"145","author":"N Alhawiti","year":"2016","journal-title":"Thromb Res"},{"issue":"1","key":"pone.0294438.ref019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"16","author":"H Haguet","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0294438.ref020","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells","volume":"11","author":"H Haguet","year":"2020","journal-title":"An In-Vitro Study. Front Pharmacol"},{"issue":"11","key":"pone.0294438.ref021","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"E Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"pone.0294438.ref022","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428194.2016.1239258","article-title":"Ponatinib reduces viability, migration, and functionality of human endothelial cells","volume":"58","author":"A Gover-Proaktor","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"pone.0294438.ref023","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/bloodadvances.2018020396","article-title":"A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML.","volume":"2","author":"S Gopal","year":"2018","journal-title":"Blood Adv"},{"key":"pone.0294438.ref024","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12872-015-0124-z","article-title":"Endothelial cell control of thrombosis","volume":"15","author":"JW Yau","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"pone.0294438.ref025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1160\/TH04-05-0306","article-title":"Role of P-selectin and PSGL-1 in coagulation and thrombosis","volume":"92","author":"ER Vandendries","year":"2004","journal-title":"Thromb Haemost"},{"issue":"2","key":"pone.0294438.ref026","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-0038-1675614","article-title":"Role of Endothelial Cells in Acute and Chronic Thrombosis.","volume":"39","author":"ML Bochenek","year":"2019","journal-title":"Hamostaseologie"},{"issue":"9","key":"pone.0294438.ref027","doi-asserted-by":"crossref","first-page":"204","DOI":"10.21037\/atm.2019.04.56","article-title":"Immunity in cancer and atherosclerosis","volume":"7","author":"P Sima","year":"2019","journal-title":"Ann Transl Med"},{"issue":"5","key":"pone.0294438.ref028","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41596-019-0144-8","article-title":"Microfabricated blood vessels for modeling the vascular transport barrier","volume":"14","author":"WJ Polacheck","year":"2019","journal-title":"Nat Protoc"},{"issue":"11","key":"pone.0294438.ref029","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1210\/en.2014-1270","article-title":"Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function","volume":"155","author":"K Barrett Mueller","year":"2014","journal-title":"Endocrinology"},{"issue":"15","key":"pone.0294438.ref030","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.lfs.2006.04.019","article-title":"Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA","volume":"79","author":"D Tang","year":"2006","journal-title":"Life Sci"},{"issue":"8","key":"pone.0294438.ref031","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"RA Larson","year":"2008","journal-title":"Blood"},{"issue":"21","key":"pone.0294438.ref032","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2011-07-369041","article-title":"Dasatinib inhibits proinflammatory functions of mature human neutrophils","volume":"119","author":"K Futosi","year":"2012","journal-title":"Blood"},{"key":"pone.0294438.ref033","first-page":"233","article-title":"Development and targeted use of nilotinib in chronic myeloid leukemia","volume":"2","author":"C Fava","year":"2009","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"pone.0294438.ref034","doi-asserted-by":"crossref","first-page":"183","DOI":"10.12793\/tcp.2017.25.4.183","article-title":"Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometry","volume":"25","author":"HB Seo","year":"2017","journal-title":"Transl Clin Pharmacol"},{"issue":"14","key":"pone.0294438.ref035","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.cub.2004.07.021","article-title":"Requirement for Abl kinases in T cell receptor signaling","volume":"14","author":"PA Zipfel","year":"2004","journal-title":"Curr Biol"},{"issue":"5","key":"pone.0294438.ref036","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2401010","article-title":"Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR\/ABL-transformed cells","volume":"12","author":"M Sattler","year":"1998","journal-title":"Leukemia"},{"issue":"23","key":"pone.0294438.ref037","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1161\/CIRCULATIONAHA.112.134304","article-title":"Effective treatment of edema and endothelial barrier dysfunction with imatinib","volume":"126","author":"J Aman","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"pone.0294438.ref038","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4161\/cam.27330","article-title":"Endothelial permeability and VE-cadherin: a wacky comradeship","volume":"7","author":"J. Gavard","year":"2013","journal-title":"Cell Adh Migr"},{"issue":"4","key":"pone.0294438.ref039","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.","volume":"32","author":"BC Medeiros","year":"2018","journal-title":"Blood Rev."},{"issue":"1","key":"pone.0294438.ref040","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1055\/s-0038-1624566","article-title":"BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?","volume":"2","author":"H Haguet","year":"2018","journal-title":"TH Open."},{"issue":"1","key":"pone.0294438.ref041","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1179\/joc.2006.18.1.56","article-title":"Modulation of vascular endothelium by imatinib: a study on the EA.hy 926 endothelial cell line.","volume":"18","author":"T Vrekoussis","year":"2006","journal-title":"J Chemother."},{"key":"pone.0294438.ref042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","article-title":"The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1beta in vascular endothelium in association with downregulation of miR-3p.","volume":"58","author":"M Sukegawa","year":"2017","journal-title":"Leuk Res."},{"issue":"5","key":"pone.0294438.ref043","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-018-0623-7","article-title":"Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option.","volume":"38","author":"A Iurlo","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"12","key":"pone.0294438.ref044","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial.","volume":"8","author":"K Murai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"pone.0294438.ref045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03007995.2017.1399870","article-title":"Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US","volume":"34","author":"M Franklin","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pone.0294438.ref046","first-page":"94","article-title":"Bleeding complications in patients with hematologic malignancies.","volume":"39","author":"M Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"21","key":"pone.0294438.ref047","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"D Rea","year":"2021","journal-title":"Blood"},{"issue":"7647","key":"pone.0294438.ref048","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"AA Wylie","year":"2017","journal-title":"Nature"},{"issue":"2","key":"pone.0294438.ref049","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cryobiol.2016.07.006","article-title":"Dimethyl sulfoxide attenuates nitric oxide generation via modulation of cationic amino acid transporter-1 in human umbilical vein endothelial cells","volume":"73","author":"OS Bentur","year":"2016","journal-title":"Cryobiology"},{"issue":"1\u20132","key":"pone.0294438.ref050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11010-011-0844-z","article-title":"Dimethyl sulfoxide induces heme oxygenase-1 expression via JNKs and Nrf2 pathways in human umbilical vein endothelial cells","volume":"355","author":"C Liang","year":"2011","journal-title":"Mol Cell Biochem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:26:33Z","timestamp":1700504793000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294438"}},"subtitle":[],"editor":[{"given":"Rama Krishna","family":"Kancha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294438","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}